Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Return on Sales (2021 - 2025)

Inmune Bio's Return on Sales history spans 5 years, with the latest figure at 1027.52% for Q3 2025.

  • For Q3 2025, Return on Sales fell 3831.0% year-over-year to 1027.52%; the TTM value through Sep 2025 reached 1027.52%, down 3831.0%, while the annual FY2024 figure was 3045.36%, 285176.0% down from the prior year.
  • Return on Sales for Q3 2025 was 1027.52% at Inmune Bio, up from 1124.58% in the prior quarter.
  • Across five years, Return on Sales topped out at 39.74% in Q1 2022 and bottomed at 3577.75% in Q2 2021.
  • The 5-year median for Return on Sales is 399.25% (2022), against an average of 758.41%.
  • The largest annual shift saw Return on Sales surged 317850bps in 2022 before it plummeted -274611bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 55.4% in 2021, then decreased by -5bps to 58.16% in 2022, then crashed by -414bps to 299.25% in 2023, then plummeted by -918bps to 3045.36% in 2024, then skyrocketed by 66bps to 1027.52% in 2025.
  • Per Business Quant, the three most recent readings for INMB's Return on Sales are 1027.52% (Q3 2025), 1124.58% (Q2 2025), and 198.1% (Q1 2025).